Cantor Fitzgerald Reiterates Overweight Rating for ALX Oncology (NASDAQ:ALXO)

ALX Oncology (NASDAQ:ALXO)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research report issued on Tuesday,Benzinga reports.

ALXO has been the topic of several other research reports. Lifesci Capital lowered shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Stifel Nicolaus reissued a “hold” rating and issued a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Tuesday, August 13th. Finally, UBS Group dropped their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 16th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $12.50.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $1.34 on Tuesday. The company’s fifty day moving average is $1.73 and its two-hundred day moving average is $5.74. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology has a 1-year low of $1.30 and a 1-year high of $17.83.

Hedge Funds Weigh In On ALX Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co bought a new stake in ALX Oncology during the 1st quarter valued at $27,000. EntryPoint Capital LLC bought a new stake in shares of ALX Oncology during the first quarter valued at about $32,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after purchasing an additional 5,200 shares during the period. SG Americas Securities LLC grew its position in ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after buying an additional 6,888 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new position in ALX Oncology during the 2nd quarter valued at about $63,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.